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Background
Most persons who are homozygous for C282Y, the HFE allele most commonly ass-
sociated with hereditary hemochromatosis, have elevated levels of serum ferritin 
and transferrin saturation. Diseases related to iron overload develop in some C282Y 
homozygotes, but the extent of the risk is controversial. 
Methods
We assessed HFE mutations in 31,192 persons of northern European descent between 
the ages of 40 and 69 years who participated in the Melbourne Collaborative Cohort 
Study and were followed for an average of 12 years. In a random sample of 1438 sub-
jects stratified according to HFE genotype, including all 203 C282Y homozygotes (of 
whom 108 were women and 95 were men), we obtained clinical and biochemical data, 
including two sets of iron measurements performed 12 years apart. Disease related 
to iron overload was defined as documented iron overload and one or more of the 
following conditions: cirrhosis, liver fibrosis, hepatocellular carcinoma, elevated ami-
notransferase levels, physician-diagnosed symptomatic hemochromatosis, and ar-
thropathy of the second and third metacarpophalangeal joints.
Results
The proportion of C282Y homozygotes with documented iron-overload–related dis-
ease was 28.4% (95% confidence interval [CI], 18.8 to 40.2) for men and 1.2% (95% CI, 
0.03 to 6.5) for women. Only one non-C282Y homozygote (a compound heterozygote) 
had documented iron-overload–related disease. Male C282Y homozygotes with a 
serum ferritin level of 1000 μg per liter or more were more likely to report fatigue, 
use of arthritis medicine, and a history of liver disease than were men who had the 
wild-type gene.
Conclusions
In persons who are homozygous for the C282Y mutation, iron-overload–related disease 
developed in a substantial proportion of men but in a small proportion of women.
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Hereditary hemochromatosis is an inherited condition of dysregulated iron absorption that can lead to total-body 
iron overload with secondary tissue damage in a 
wide range of organs. Left untreated, this condi-
tion can result in diseases such as hepatic cirrho-
sis and hepatocellular carcinoma.1,2 Disease can 
be prevented by decreasing the body’s iron stores, 
through either regular blood donation or thera-
peutic venesection.3,4 Cirrhosis most commonly 
occurs in patients with a homozygous substitution 
of tyrosine for cysteine at position 282 (C282Y) in 
the HFE protein who have serum ferritin levels of 
more than 1000 μg per liter.4,5 Patients with he-
reditary hemochromatosis can have a normal life 
expectancy if treatment is started before cirrhosis 
occurs.6
Persons who are homozygous for the C282Y 
mutation are at increased risk for iron overload. 
C282Y homozygotes account for 82 to 90% of 
clinical diagnoses of hereditary hemochromatosis 
among persons of northern European descent.7 
C282Y homozygotes can be characterized by the 
stage of progression as follows: a genetic predispo-
sition without abnormalities, iron overload with-
out symptoms, iron overload with symptoms (e.g., 
arthritis and fatigue), and iron overload with organ 
damage — in particular, cirrhosis.8
The prevalence of C282Y homozygosity is ap-
proximately 1 case per 200 persons, with elevated 
levels of serum ferritin and transferrin saturation 
occurring in 40 to 60% of female homozygotes 
and in 75 to 100% of male homozygotes.9-13 An 
elevated serum ferritin level is a necessary but not 
sufficient prerequisite for the diagnosis of iron 
overload, which can be objectively documented ei-
ther by liver biopsy with determination of quanti-
tative hepatic iron levels or by quantitative phle-
botomy.14
The presence of cirrhosis, severe fibrosis, he-
patocellular carcinoma, or arthropathy of the sec-
ond and third metacarpophalangeal joints in the 
context of documented iron overload and C282Y 
homozygosity constitutes iron-overload–related 
disease in patients with hereditary hemochroma-
tosis.15-17 It is not known whether other compli-
cations that are associated with the disease (e.g., 
fatigue, abdominal pain, and diabetes) can be at-
tributed to an abnormal HFE genotype, particu-
larly since these conditions are common and 
nonspecific. Population estimates of both doc-
umented disease related to iron overload and con-
ditions associated with hereditary hemochroma-
tosis in C282Y homozygotes have been hindered by 
the absence of clinical assessment before knowl-
edge of the patient’s genetic status or by an inabil-
ity to account for the long lead time of preclini-
cal iron-overload status.
In this 12-year study involving a cohort of 
31,192 subjects, we prospectively assessed the 
prevalence of iron-overload–related disease, along 
with morbidity and mortality, for C282Y homozy-
gotes, as compared with three groups of subjects: 
those with compound heterozygosity for C282Y 
and the substitution of aspartic acid for histidine 
at position 63 (H63D), C282Y heterozygotes, and 
subjects with neither HFE variant.
Me thods
Study Population
From 1990 to 1994, a total of 41,528 subjects (in-
cluding 24,479 women) between the ages of 27 and 
75 years (of whom 99% were between the ages of 
40 and 69 years) were enrolled in the Melbourne 
Collaborative Cohort Study,18 which is a prospec-
tive longitudinal study of diet and other lifestyle 
factors and the influence of these factors on the 
development of common chronic diseases. Subjects 
were recruited through the Australian Electoral 
Roll (voting is compulsory in Australia), advertise-
ments, and community announcements in local 
media. After recruitment, subjects visited a study 
center, where they were interviewed about a range 
of lifestyle and dietary factors, underwent physi-
cal measurement, and provided a blood sample.
For this study (known as HealthIron), subjects 
who were born in southern Europe (Italy, Greece, 
and Malta) were excluded, owing to the low preva-
lence of the C282Y variant in those populations. 
This exclusion left 31,192 subjects who reported 
having been born in Australia, the United King-
dom, Ireland, or New Zealand (i.e., of northern 
European ancestry), with a mean (±SD) age of 
55.3±8.9 years. At baseline, 7270 of 17,951 women 
(40.5%) reported that they were premenopausal; 
the menopausal status of 1313 women was un-
known. All subjects were included in the analysis 
of mortality. For analyses of other outcomes, a 
random sample of 1438 subjects who were strati-
fied according to HFE genotype and included all 
C282Y homozygotes were invited to undergo a 
clinical assessment as part of the HealthIron study. 
Deaths that occurred before December 31, 2004, 
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were identified through linkage to death records 
of the state of Victoria and the Australian National 
Death Index.
Preliminary HFE Genotyping
For 23,484 subjects, DNA from stored baseline 
samples was extracted from Guthrie cards with the 
use of Chelex reagent. For 7708 subjects, DNA was 
extracted with the use of buffy-coat CorProtocol 
14102 (Corbett Life Science) from frozen blood 
fractions stored in liquid nitrogen. All samples 
were genotyped for nucleotide changes that cor-
respond to the amino acid substitution C282Y and 
H63D in HFE with the use of the Taqman real-time 
polymerase-chain-reaction (PCR) assay (Applied 
Biosystems), as described previously.11,19 Owing to 
initial difficulties with the assay of DNA samples 
extracted from Guthrie cards, genotyping for the 
H63D variant was performed only among subjects 
who were heterozygous for the C282Y variant. Ge-
notyping of 29,676 of the 31,192 samples (95.1%) 
was successful.
HealthIron Clinics
From 2004 to 2006, letters of invitation to partici-
pate in the HealthIron study were sent to a sam-
ple of 1438 subjects that included all C282Y homo-
zygotes and a stratified random sample of subjects 
from the remaining groups with the HFE geno-
type. Investigators were unaware of subjects’ HFE 
genotype until all clinical assessments had been 
completed. Before being interviewed and under-
going clinical examination, subjects were asked by 
the clinic manager not to reveal to the study phy-
sicians any previous diagnosis of iron overload or 
hemochromatosis.
Subjects completed a computer-assisted per-
sonal interview and provided a cheek-brush sample 
for confirmatory HFE genotyping. Blood samples 
were collected for measurement of iron indexes 
and liver enzyme levels with the use of automated 
assays (Roche Diagnostics) and were paired for 
analysis with the corresponding stored baseline 
serum samples. Blood samples were collected in 
the morning at both baseline and follow-up.
Study investigators performed a physical ex-
amination of the abdomen and metacarpophalan-
geal joints. Previously unidentified C282Y homo-
zygotes were referred to a HealthIron follow-up 
clinic for ongoing treatment and a liver biopsy, 
if clinically indicated. Results of previous liver bi-
opsy were obtained from physicians of C282Y ho-
mozygotes whose condition had been diagnosed 
before or during the course of the study. The defi-
nitions of iron overload and iron overload–related 
disease are listed in Table 1.
All subjects gave written informed consent to 
participate in both the Melbourne Collaborative 
Cohort Study and the HealthIron study. Both study 
protocols were approved by the ethics committee 
at the Cancer Council Victoria.
Statistical Analysis
Prevalences were estimated as observed propor-
tions and compared by calculating prevalence 
ratios and 95% confidence intervals. Genotype 
groups were compared by analysis of variance for 
continuous measures, with serum ferritin ana-
lyzed on the natural logarithm scale, or by chi-
square tests for proportions. Cox regression with 
age as the time axis was used to estimate the haz-
ard ratio for the association between the HFE gen-
otype and death. The proportional-hazards as-
sumption was assessed by means of plots of the 
Nelson–Aalen estimate of the cumulative hazard 
and formal tests based on Schoenfeld residuals. 
Table 1. Definitions of Categories of Iron Overload and Iron-Overload–
Related Disease.*
Variable Clinical Finding or Laboratory Measure
Iron overload
Documented At least one of the following: increased iron content 
shown by hepatic iron staining 3 or 4, iron con-
centration >90 μmol per gram, or hepatic iron  
index >1.9 (Whitlock et al.14) or serum ferritin 
>1000 μg per liter at baseline with documented 
therapeutic venesection
Provisional Elevated serum ferritin (>300 μg per liter for men 
and postmenopausal women, >200 μg per liter 
for premenopausal women) in association with 
elevated transferrin saturation (>55% for men 
and >45% for women)
No evidence Either normal or elevated serum ferritin with normal 
transferrin saturation
Iron-overload–related 
disease
At least one of the following plus documented iron 
overload: hepatocellular carcinoma, cirrhosis or 
fibrosis on percutaneous liver biopsy, tenderness 
or effusion of the second and third metacarpo-
phalangeal joints, elevated levels of serum aspar-
tate aminotransferase (>45 IU per liter) or serum 
alanine aminotransferase (>40 IU per liter), or di-
agnosis by a physician owing to symptoms asso-
ciated with hereditary hemochromatosis
* Documented iron-overload–related disease was considered to be present if 
subjects had both documented iron overload and evidence of iron-overload–
related disease.
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Statistical analyses were performed with the use 
of Stata software, version 9.1 (Stata).
R esult s
Whole-Cohort Analysis
Among 29,676 subjects of northern European an-
cestry, 203 were homozygous for the C282Y mu-
tation, which corresponded to an estimated prev-
alence of 1 case per 146 subjects, or 0.68% (95% 
confidence interval [CI], 0.59 to 0.78). The pres-
ence of homozygosity for the C282Y mutation was 
confirmed in an independent laboratory from ei-
ther a follow-up cheek swab or a baseline serum 
sample.
There were 3295 subjects (11.1%) who were 
heterozygous for the C282Y mutation only. An ad-
ditional 719 subjects (2.4%) were heterozygous for 
both the C282Y and H63D mutations (compound 
heterozygotes). The observed number of both 
simple (C282Y) and compound (C282Y–H63D) het-
erozygotes in the whole cohort was lower than 
expected on the basis of Hardy–Weinberg equilib-
rium (chi-square = 6.25, P = 0.01). With the excep-
tion of C282Y homozygotes, this baseline genotyp-
ing was not repeated with a second, independent 
method.
Death from Any Cause
During an average of 11.4 years of follow-up, 2488 
subjects (8.0%) died, including 19 of 203 C282Y ho-
mozygotes (9.4%), 59 of 719 compound heterozy-
gotes (8.2%), and 295 of 3295 C282Y heterozygotes 
(9.0%). The hazard ratio for death from any cause 
among the C282Y homozygotes, as compared with 
subjects who had no C282Y mutation, was 1.04 
(95% CI, 0.67 to 1.62; P = 0.87).
HealthIron Subjects 
Of the 1438 subjects who were invited to partici-
pate in the HealthIron study, 1054 (73.3%) com-
pleted at least two of the four components: a ques-
tionnaire, confirmatory HFE genotyping, blood 
sampling, and physical examination; 937 subjects 
(65.2%) completed all components, 58 (4.0%) com-
pleted three components (excluding physical ex-
amination), and 59 (4.1%) completed only the ques-
tionnaire and genotyping. Of the 384 subjects who 
did not complete any of the four components of 
the final study, 113 had died, 197 were no longer 
actively participating in the study, and 74 could 
not be contacted. A total of 1054 of the 1325 sub-
jects who were still alive participated (79.5%). The 
male:female ratio and median ages at baseline and 
follow-up did not differ significantly among the 
HFE genotype groups (Table 2).
Of 142 C282Y homozygotes (66 of whom were 
men) who participated in follow-up assessments, 
12 (8.5%) had received the diagnosis of hemochro-
matosis as part of usual care before the baseline 
assessment for the Melbourne Collaborative Co-
hort Study, 52 (36.6%) received the diagnosis after 
baseline but before the clinical assessments for the 
HealthIron study, and 78 (54.9%) were informed 
after undergoing the HealthIron follow-up assess-
ments. C282Y homozygotes with a baseline or 
follow-up serum ferritin level of 1000 μg per liter 
or more were more likely to have received the di-
agnosis of hereditary hemochromatosis during 
routine care and before follow-up than were those 
with a serum ferritin level of less than 1000 μg per 
liter (23 of 37 subjects [62.2%] vs. 41 of 105 sub-
jects [39.0%], P = 0.02). Among the 64 subjects 
in whom hereditary hemochromatosis was diag-
nosed before follow-up, the diagnosis was the 
result of an assessment of symptoms for 18 sub-
jects (28.1%), follow-up of family members for 
20 subjects (31.2%), and routine blood tests for 
13 subjects (20.3%); the reason was unknown 
for 13 subjects (20.3%).
Serum Ferritin and Transferrin Saturation
Of the 1438 subjects who participated in the 
HealthIron study, 850 (59.1%) were fasting when 
the baseline blood sample was obtained, and 941 
of 1054 (89.3%) were fasting when the follow-up 
sample was obtained. At baseline, among C282Y 
homozygotes, the level of serum ferritin was more 
than 300 μg per liter in 45 of 55 men (81.8%) and 
more than 200 μg per liter (>300 μg per liter for 
postmenopausal subjects) in 36 of 65 women 
(55.4%). In the same group, transferrin saturation 
was more than 55% in 40 of 55 men (72.7%) and 
more than 45% in 45 of 65 women (69.2%). At least 
one serum ferritin value of 1000 μg per liter or 
more was recorded in 33 of 74 men (44.6%) and in 
7 of 84 women (8.3%) (Table 2).
For men, the mean serum ferritin level de-
creased during the 12-year period from baseline 
to follow-up in all HFE genotype groups (Table 2), 
although there were large changes for only two 
subgroups of subjects: C282Y homozygotes, who 
had a mean reduction from 1195 μg per liter to 
593 μg per liter, including 30% of subjects who had 
undergone therapeutic venesection, and compound 
heterozygotes, who had a mean reduction from 
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351 μg per liter to 264 μg per liter. In contrast, 
the mean serum ferritin level increased in women 
for all genotype groups during the study period 
(Table 2), except for C282Y homozygotes, of whom 
20% had undergone therapeutic venesection. Male 
C282Y homozygotes (including those who under-
went venesection) were the only group in which the 
mean transferrin saturation changed significantly 
between baseline and follow-up (a decrease from 
73±3% to 63±3%) (P = 0.03), although only 64% of 
male C282Y homozygotes were fasting at the time 
of the baseline sampling, as compared with 100% 
at follow-up.
Clinical Features According to HFE Genotype
Male C282Y homozygotes with serum ferritin lev-
el of 1000 μg per liter or more at baseline or fol-
low-up had a higher prevalence of reported fatigue, 
liver disease, and use of arthritis medication than 
did subjects with the wild-type gene and C282Y 
heterozygotes combined. In addition, a higher pro-
portion of male C282Y homozygotes had increased 
levels of alanine aminotransferase or aspartate 
aminotransferase in the absence of excess alco-
hol intake (Table 3).
The presence of abnormal second and third 
metacarpophalangeal joints was more common 
in male C282Y homozygotes than in control sub-
jects, regardless of serum ferritin levels. In con-
trast, the use of arthritis medication and elevated 
levels of alanine aminotransferase or aspartate 
aminotransferase were the only features associated 
with hereditary hemochromatosis that were more 
commonly reported for female C282Y homozy-
gotes with a serum ferritin level of more than 
1000 μg per liter than for C282Y heterozygotes 
or those with the wild-type gene.
Iron Overload and Related Disease
For C282Y homozygotes, 21 of 74 men (28.4%; 
95% CI, 18.8 to 40.2) and 1 of 84 women (1.2%; 
95% CI, 0.03 to 6.5) satisfied the criteria for doc-
umented disease related to iron overload (Tables 1 
and 4). Of the 22 C282Y homozygotes with docu-
mented iron overload–related disease, 2 had hepa-
tocellular carcinoma, 12 had fibrosis or cirrhosis, 
6 had raised levels of alanine aminotransferase 
or aspartate aminotransferase, 5 had abnormal 
metacarpophalangeal joints, and 11 had received 
a previous diagnosis of hereditary hemochroma-
tosis as a result of symptoms that prompted an 
evaluation.
For 40 C282Y homozygotes, liver biopsies were 
clinically indicated because of a serum ferritin 
level of 1000 μg per liter or more.4,5 Of these sub-
jects, 17 (including 16 men) underwent liver biopsy 
(42.5%); all subjects had an iron grade of 2 or 
more, and 12 had liver cirrhosis or fibrosis.
Four of the liver biopsies were performed be-
fore baseline, with grade 1 fibrosis observed in a 
22-year-old subject, grade 0 in a 42-year-old sub-
ject, grade 3 in a 64-year-old subject, and grade 0 
in a 67-year-old subject. Seven liver biopsies were 
performed after baseline and before follow-up, 
with grade 2 fibrosis observed in both a 57-year-
old subject and a 58-year-old subject with self-
reported alcoholic liver disease, grade 1 in a 
58-year-old subject, and grade 0 in a 59-year-old 
subject; cirrhosis in a 62-year-old subject and a 
71-year-old subject; and grade 3 fibrosis in a 76-
year-old subject who consumed more than 100 g 
of alcohol per day. Six biopsies were performed in 
subjects who were referred to a hepatologist after 
they had undergone follow-up assessments at the 
HealthIron study clinic, with grade 0 fibrosis ob-
served in a 54-year-old subject and a 55-year-old 
subject and grade 1 in three 56-year-old subjects 
and one 59-year-old subject.
No subjects with biopsy results reported having 
had viral hepatitis, and only one (as noted above) 
reported having a high baseline level of alcohol 
consumption (>40 g per day for women and >60 g 
per day for men). Only one subject who was not 
a C282Y homozygote (a compound heterozygote) 
had documented iron-overload–related disease.
Provisional Iron Overload and Related 
Disease
Provisional iron overload (defined in Table 1) oc-
curred in six compound heterozygotes, in two 
C282Y heterozygotes, in one H63D heterozygote, 
and in two subjects with neither mutation. Only 
one of the two subjects with neither mutation had 
evidence of iron-overload–related disease. In com-
parison, 83 C282Y homozygotes (both men and 
women) had provisional iron overload; of these 
subjects, 24% had objective evidence of iron-over-
load–related disease (Table 4).
Discussion
In a prospective cohort study with more than 12 
years of follow-up, for C282Y homozygotes, doc-
umented iron-overload–related disease developed 
in 28.4% of men but only 1.2% of women. C282Y 
homozygotes with a serum ferritin level of 1000 μg 
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Table 2. Demographic and Clinical Characteristics of 1290 Subjects, According to HFE Genotype.*
Variable
C282Y  
Homozygote
Compound  
Heterozygote
C282Y  
Heterozygote
H63D Heterozygote 
or Homozygote
No C282Y or 
H63D Mutation P Value†
Subjects in HealthIron study — no.‡ 203 242 337 147 361
Median age at follow-up — yr 65.2 64.6 63.2 66.6 66.0 0.33
Male sex — no. (%) 95 (46.8) 117 (48.3) 161 (47.8) 61 (41.5) 164 (45.4) 0.74
Serum ferritin§ 
At baseline 
No. of men 55 69 100 42 130
Value — μg/liter 1195±182 351±41 250±21 266±27 216±15 <0.001
No. of women 65 72 112 71 158
Value — μg/liter 374±52 124±13 93±9 128±16 90±7 <0.001
At follow-up
No. of men 61 78 107 52 139
Value — μg/liter 593±90 264±22 229±16 193±28 199±16 0.001
No. of women 73 90 125 76 169
Value — μg/liter 355±38 159±11 136±11 139±14 118±9 <0.001
Transferrin saturation 
At baseline
No. of men 55 69 100 43 132
Value — % 73±3 42±1 35±1 34±2 30±1 <0.001
No. of women 65 72 113 72 158
Value — % 53±3 37±2 30±1 28±1 25±1 <0.001
At follow-up
No. of men 61 78 107 52 140
Value — % 63±3 40±1 33±1 32±2 29±1 <0.001
No. of women 73 91 127 76 169
Value — % 54±2 39±1 31±1 27±1 25±1 <0.001
Any serum ferritin ≥1000 μg per liter 
— no./total no. (%)¶
Men 33/74 (44.6) 2/90 (2.2) 2/129 (1.6) 1/54 (1.9) 2/150 (1.3) <0.001
Women 7/84 (8.3) 0/98 0/144 0/84 0/181 <0.001
Blood donation
Any donation — no./total no. (%)
Men 35/66 (53.0) 43/84 (51.2) 67/117 (57.3) 28/52 (53.8) 78/142 (54.9) 0.92
Women 36/77 (46.8) 46/95 (48.4) 66/139 (47.5) 41/79 (51.9) 85/176 (48.3) 0.97
Average lifetime donations (ex-
cluding therapeutic 
venesection)‖
No. of men 32 40 61 27 74
No. of donations 39.6±5.9 50.6±6.3 40.6±7.0 25.2±5.1 47.2±5.2 0.42
No. of women 35 39 56 33 76
No. of donations 28.2±6.1 27.3±4.2 26.7±3.8 27.9±4.6 27.2±3.2 0.95
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per liter or more were at higher risk for symptoms 
and disease associated with the HFE gene than were 
either C282Y homozygotes with a serum ferritin 
level of 1000 μg per liter or less or subjects with 
other HFE genotypes. This finding confirms and 
extends the observation of Guyader and colleagues5 
that a serum ferritin level of 1000 μg per liter or 
more is associated not only with cirrhosis but also 
with symptomatic hereditary hemochromatosis in 
C282Y homozygotes. Arthropathy, as defined by 
clinically abnormal metacarpophalangeal joints, 
was unrelated to serum ferritin levels in homozy-
gotes, a finding that confirmed results reported 
previously.17
Investigators who conducted clinical examina-
tions were not aware of the genotype of the study 
subjects. Our estimate of disease penetrance (the 
probability of expression of a genotype) is conser-
vative, since we used strictly objective criteria on 
the basis of liver biopsy, liver-enzyme levels, clini-
cal examination, or physicians’ diagnosis in the 
context of documented iron overload. Subjective 
criteria such as a history of fatigue or liver dis-
ease were excluded from our assessment of dis-
ease penetrance. Detailed data on lifestyle factors 
were collected as part of the study. Because male 
C282Y homozygotes were not significantly more 
likely to be obese and did not have greater alcohol 
intake than male subjects who were not C282Y 
homozygotes, these factors are unlikely to explain 
the increased prevalence of elevated levels of ala-
nine aminotransferase or aspartate aminotrans-
ferase among male C282Y homozygotes.
The high prevalence of C282Y homozygosity in 
this study may be attributable to a high rate of 
British immigration in this age group in Mel-
bourne.20 This high prevalence of C282Y homo-
zygosity makes it unlikely that patients who had 
received the diagnosis of hereditary hemochroma-
tosis previously were underrepresented in our ini-
tial recruitment, and linkage to the National Death 
Index minimized selective mortality bias. Thirty-
Table 2. (Continued.)
Variable
C282Y  
Homozygote
Compound  
Heterozygote
C282Y  
Heterozygote
H63D Heterozygote 
or Homozygote
No C282Y or 
H63D Mutation P Value†
Alcohol consumption
Nondrinkers at baseline —  
no./total no. (%)
Men 7/67 (10.4) 15/84 (17.9) 17/118 (14.4) 14/55 (25.5) 21/149 (14.1) 0.19
Women 19/79 (24.1) 27/96 (28.1) 38/139 (27.3) 34/84 (40.5) 73/181 (40.3) 0.01
Consumption at baseline
No. of men 60 69 101 41 128
Grams per day 17±2 23±2 21±2 21±2 23±2 0.39
No. of women 60 69 101 50 108
Grams per day 11±2 11±1 15±1 13±2 12±1 0.26
Obesity (BMI >30) at baseline —  
no./total no. (%)**
Men 4/95 (4.2) 23/117 (19.7) 19/161 (11.8) 11/61 (18.0) 28/164 (17.1) 0.07
Women 14/108 (13.0) 20/125 (16.0) 22/176 (12.5) 9/86 (10.5) 36/197 (18.3) 0.40
* Plus–minus values are means ±SD. 
† P values are for comparisons of genotype groups by analysis of variance for means or chi-square tests for proportions.
‡ An additional 148 subjects were selected to participate in the study but did not undergo full genotyping for HFE: 132 had no copies of 
C282Y but did not undergo genotyping for H63D, and 16 did not undergo genotyping for either locus.
§ At baseline, 4 male and 1 female C282Y homozygotes received the diagnosis of hereditary hemochromatosis and started therapeutic vene-
section, as did 25 male and 17 female C282Y homozygotes during the study period.
¶ Among subjects with a serum ferritin level of 1000 μg per liter or more, all the C282Y homozygotes, one male compound heterozygote, and 
one male subject with neither mutation also had an elevated transferrin saturation.
‖ In Australia, one blood donation usually consists of 450 ml (i.e., 1 unit) of blood.
** The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
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Table 3. Prevalence of Clinical Features Associated with Hereditary Hemochromatosis, According to HFE Genotype.*
Variable C282Y Homozygote
Compound  
Heterozygote
H63D  
Homozygote 
or Heterozygote
C282Y  
Heterozygote or 
Wild Type
C282Y Homozygote  
with Serum Ferritin >1000 µg  
per Liter versus Wild-Type  
or C282Y Heterozygote
Serum Ferritin 
≥1000 μg/liter
Serum Ferritin 
<1000 μg/liter
Prevalence Ratio 
(95% CI) P Value
No. of subjects
Men 33  62 117 60 325
Women  7 101 125 86 373
no./total no. (%)
Fatigue†
Men 7/30 (23.3) 5/35 (14.3) 9/84 (10.7) 8/52 (15.4) 24/259 (9.3) 2.52 (1.19–5.34) 0.02
Women 1/7 (14.3) 14/69 (20.3) 15/94 (16.0) 14/80 (17.5) 58/315 (18.4) 0.78 (0.12–4.83) 0.78
Abnormal metacarpo-
phalangeal 
joints‡
Men 6/25 (24.0) 7/24 (29.2) 13/64 (20.3) 8/45 (17.8) 29/210 (13.8) 1.74 (0.80–3.77) 0.18§
Women 1/ 4 (25.0) 6/56 (10.7) 16/80 (20.0) 9/63 (14.3) 24/247 (9.7) 2.57 (0.45–14.65) 0.31
Use of arthritis medicine 
at baseline¶
Men 3/33 (9.1) 7/63 (11.1) 2/117 (1.7) 2/60 (3.3) 7/325 (2.2) 4.22 (1.15–15.55) 0.02
Women 5/7 (71.4) 9/101 (8.9) 12/125 (9.6) 9/86 (10.5) 25/373 (6.7) 10.66 (5.83–19.47) <0.001
AST >45 IU/liter or ALT 
>40 IU/liter‖
Men 6/27 (22.2) 4/33 (12.1) 6/74 (8.1) 5/50 (10.0) 21/233 (9.0) 2.47 (1.09–5.57) 0.03
Women 2/5 (40.0) 3/66 (4.5) 1/89 (1.1) 0/74 12/287 (4.2) 9.57 (2.86–32.02) <0.001
Hepatomegaly**
Men 0/23 1/23 (4.3) 5/62 (8.1) 0/45 8/204 (3.9) 0 (0–0.05) 0.33
Women  0/4 1/56 (1.8) 1/77 (1.3) 2/61 (3.3) 4/233 (1.7) 0 (0–0.09) 0.79
History of liver disease†
Men 5/30 (16.7) 1/35 (2.9) 6/84 (7.1) 4/52 (7.7) 7/258 (2.7) 6.14 (2.08–18.15) <0.001
Women 0/7 5/68 (7.4) 4/93 (4.3) 5/79 (6.3) 23/315 (7.3) 0 (0–0.01) 0.46
Diabetes††
Men 1/33 (3.0) 2/63 (3.2) 4/117 (3.4) 3/60 (5.0) 9/325 (2.8) 1.09 (0.14–8.37) 0.93
Women 0/7 0/101 2/125 (1.6) 4/86 (4.7) 4/373 (1.1) 0 (0–0.07) 0.78
* Among C282Y homozygotes with a serum ferritin level of 1000 μg per liter or more at baseline or follow-up, only two men and one woman 
had three or more features; among those who did not have a serum ferritin level of 1000 μg per liter or more, one woman had three or 
more features. ALT denotes alanine aminotransferase, AST aspartate aminotransferase, and CI confidence interval.
† Data are for subjects who reported having this condition at follow-up.
‡ This condition was defined as a bony spur or tenderness or effusion on both the second and third metacarpophalangeal joints on either 
hand, as determined by a physician who was unaware of genotype at follow-up.
§ For the comparison of combined C282Y homozygotes with combined C282Y heterozygotes and subjects with a wild-type gene, the preva-
lence ratio was 1.92 (95% CI, 1.08 to 3.42; P = 0.03).
¶ At baseline, the use of arthritis drugs was established by the subject’s response to the question “Has the doctor ever told you that you 
have had arthritis or rheumatism?” followed by “If you have arthritis or rheumatism, do you take aspirin?”
‖ Excluded from this category were subjects with a daily alcohol intake of more than 60 g for men or more than 40 g for women.
** Liver enlargement was defined as a liver span of 13 cm or more as assessed during blinded clinical examination at follow-up.
†† Data are for subjects who reported that they had physician-diagnosed diabetes at baseline.
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seven percent of C282Y homozygotes were identi-
fied during follow-up, which may have modified 
the natural history of disease progression for these 
subjects and resulted in an underestimation of 
disease penetrance. Our study did not address the 
association of HFE mutations with less commonly 
reported features of hereditary hemochromatosis, 
such as impotence and cardiomyopathy.
Two other longitudinal studies have attempted 
to characterize the penetrance of disease related 
to hereditary hemochromatosis with the use of 
population-based data.12,21 Andersen and col-
leagues12 retrospectively assessed 23 C282Y homo-
zygotes (including 16 women) during a 25-year 
period and found no evidence of liver disease as-
sociated with hereditary hemochromatosis. How-
ever, the study was potentially compromised by 
selective mortality bias, owing to the high rate of 
attrition in the cohort (53%), the fact that 35% of 
the members of the original cohort were not geno-
typed for HFE mutations, and the fact that 3 of the 
23 C282Y homozygotes died before they could be 
examined. Olynyk and colleagues,21 who retro-
spectively assessed 10 C282Y homozygous patients 
(including 6 women) during a 17-year period, re-
ported that of the 6 patients who underwent liver 
biopsy, 3 had cirrhosis or fibrosis. However, not 
all the patients in that study were at an age when 
symptoms of disease would have been expected. 
In a systematic review, Whitlock and colleagues14 
estimated, after accounting for patients who were 
lost to follow-up, that disease would eventually 
develop in 25 to 60% of C282Y homozygotes.
On the basis of a cross-sectional population 
study of subjects between the ages of 20 and 80 
years (an age range that was wider than that of 
our study and that included a greater proportion 
of subjects under the age of 50 years), Beutler and 
colleagues10 suggested that disease attributable to 
hereditary hemochromatosis occurred in less than 
1% of all C282Y homozygotes, regardless of sex. 
However, Beutler et al. did not perform clinical 
examinations or liver biopsies, and a quarter of the 
C282Y homozygotes were excluded on the basis 
that they had received a previous diagnosis of he-
reditary hemochromatosis. This exclusion would 
be expected to reduce the estimate of clinical pen-
etrance of C282Y homozygosity.22,23 Contrary to 
our results, Beutler et al. found no association be-
tween C282Y homozygosity and the presence of 
fatigue or arthritis, although they reported an as-
sociation with a history of liver disease. The ex-
clusion of subjects in whom hereditary hemochro-
matosis had already been diagnosed might account 
Table 4. Categorization of Iron Overload and Iron-Overload–Related Disease among C282Y Homozygotes.*
Variable
Disease Associated  
with Hereditary  
Hemochromatosis
No Disease Associated  
with Hereditary  
Hemochromatosis Total
no. (%)
Documented iron overload
Men 21 (28.4) 6 (8.1) 27
Women 1 (1.2) 2 (2.4) 3
Provisional iron overload
Men 10 (13.5) 22 (29.7) 32
Women 10 (11.9) 41 (48.8) 51
No evidence of iron overload
Men 2 (2.7) 13 (17.6) 15
Women 6 (7.1) 24 (28.6) 30
Total
Men 33 41 74
Women 17 67 84
* Complete definitions of iron-overload and iron-overload–related disease are listed in Table 1. Percentages are for 158 
C282Y homozygotes (74 men and 84 women) for whom at least one serum ferritin measurement was available. Of 
those subjects, 142 underwent follow-up assessments, 14 died during the study, and 2 did not undergo follow-up 
 assessments for other reasons.
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for this finding, since our study showed that sub-
jects with a serum ferritin level of 1000 μg per 
liter or more were more likely to present with 
symptoms than were those with a level of less 
than 1000 μg per liter.
The increased prevalence of iron-overload–
related disease in C282Y homozygous men, as 
compared with that in women, is frequently as-
cribed to recurrent physiologic blood loss and the 
resultant slower accumulation of iron in women. 
However, disparate frequencies of HLA A*03B*07 
haplotypes in men and women have been reported 
in hereditary hemochromatosis probands,24 which 
may be relevant to sex-specific phenotypic expres-
sion of this disease. Studies of iron regulatory 
pathways in African Americans have also sug-
gested that serum ferritin levels may be genetically 
determined by sex differences as well as environ-
mental factors.25,26
In conclusion, disease related to iron overload 
commonly develops in men (but not in women) 
who are homozygous for the C282Y mutation, es-
pecially when serum ferritin levels are 1000 μg per 
liter or more.
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